2020 Revenues ($USD) : $4,017,120,014 2020 Revenues (foreign currencies) : RMB27,735,000,000 2020 R&D spend : $722,603,633 2020 Number of Employees : 28,903 Fiscal Year End : 12/31/2020 Key People : Zhou Yunshu, chair & president
Publicly traded on the Shanghai Stock Exchange, Jiangsu Hengrui Medicine boasts over 100 pipelines and products across therapeutic areas such as oncology, metabolics, autoimmune, pain management. In China, it has established a National Targeted Drug Engineering Technology Research Center. HengRui USA’s headquarters are in Princeton, N.J. –CN